Vol. 2 No. 5 (2019): International Journal of Aging Research
Research Articles

Use and preventive value of metformin in geriatric women with polycystic ovary syndrome

Jazmín Abril Pérez Aguilar, Alejandra Niño Herrera, Guillermo Muñoz Zurita
Facultad de Medicina Benemérita Universidad Autónoma de Puebla
Keywords
  • Metformin, Geriatrics, Syndrome, Ovaries, Polycystic
How to Cite
Jazmín Abril Pérez Aguilar, Alejandra Niño Herrera, Guillermo Muñoz Zurita. (2019). Use and preventive value of metformin in geriatric women with polycystic ovary syndrome. International Journal of Aging Research, 2(5). https://doi.org/10.28933/ijoar-2019-11-2605

Abstract

Objective: To establish the effects of long-term use and preventive value of metformin in geriatric women with PCOS.

Methods: A search of published review articles was carried out in sites such as NCBI, ScienceDirect, Elsevier, Springer, Wolters Kluwer, among others, using the key words: “polycystic ovary syndrome”, “PCOS”, “Polycystic ovary syndrome and metformin”, “effects of metformin and PCOS“,” insulin resistance and metformin “and” long-term sequelae of polycystic ovarian syndrome“.

Results: We retrospectively analyzed data specific to the randomized clinical trial of Pedersen et al. 2017, to determine the impact that treatment had for twelve months with metformin in three specific variables: weight, total cholesterol and HDL. The study was conducted in 40 Caucasian women from 18 to 39 years of age, with a fixed dose of metformin (2 g / day for 12 months), who met the Rotterdam criteria for PCOS in their genetic variant MATE1 with SOP7.

Conclusions: It was confirmed that the establishment of twelve-month treatment with metformin in the randomized clinical trial of Pedersen et al. 2017 had a significant effect on the three specific variables: weight, total cholesterol and HDL.

References

  1. Lashen H. Role of metformin in the management of polycystic ovary syndrome. 2010: 117-28.
  2. Imthurn B, Mueck AO, Ortmann O. Metformin und das Syndrom der polyzystischen Ovarien. Gynäkologische Endokrinol. 2018; 16: 191-4.
  3. Nature S, Medizin I. Das Syndrom polyzystischer Ovarien und Metformin. 2018; (September 2017): 10-13.
  4. Andrade MA, Arana GG, Barriga R.N. Metformin as the basis for the treatment of polycystic ovarian syndrome MedPre. (April): 15-21.
  5. Rosenblum J. EL. Polycystic Ovary Syndrome .; 2017
  6. Pedersen AJT, Stage TB, Glintborg D, Andersen M, Marie M, Christensen H. The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. 2018: 239-44.
  7. Johnson NP. Metformin use in women with polycystic ovary syndrome. Ann Transl Med. 2014; 2 (6): 56.
  8. Macut D. Insulin and polycystic ovary syndrome. 2017
  9. Ou H, Chen P, Wu M, Lin C. Metformin improved health-related quality of life in ethnic Chinese women with polycystic ovary syndrome. Health Qual Life Outcomes. 2016: 1-10.
  10. F.-F. Wang, Y. Wu, Y.-H. Zhu, T. Ding, R. L. Batterham, F. Qu and PJH. Pharmacologic therapy to induce weight loss in women who have obesity / overweight with polycystic ovary syndrome: a systematic review and network. Obes Rev. 2018; (October): 1424-45.
  11. Sam S, Ehrmann DA. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetology 2017; 60: 1656-61.
  12. Diamanti E, Economou F, First CC, Diamanti E. Abstract Introduction Mechanisms of action of metformin in different. 2010; 1205 (1).
  13. Zhang Y, Hu M, Meng F, et al. EBioMedicine Metformin Ameliorates Uterine Defects in a Rat Model of Polycystic Ovary Syndrome. EBioMedicine. 2017; 18: 157-70.
  14. Diamanti-kandarakis E, Economou F, Palimeri S. Metformin in polycystic ovary syndrome. 2010; 1205: 192-8.
  15. Luque-ramírez M, Nattero-chávez L, Flores AEO, Escobar-morreale HF. Combined oral contraceptives and / or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2018; 24 (2): 225-41.